Cassava Sciences Announced Simufilam Results for Alzheimer's
Cassava Sciences (SAVA) announced impressive results of an interim analysis from an open-label study of simufilam, a drug candidate for the treatment of Alzheimer’s disease. Simufilam improved both patients’ cognition and behavior scores following six months of treatment. There were no safety issues.
In a clinical study funded by the National . . .
This content is for paid subscribers.
Today’s Highlights February 2, 2021